CORRECTION

In the Letter to the Editor “An Opportunity to Report Closer-to-Efficacy Findings in a Study of Lamotrigine for Borderline Personality Disorder,” by Eric G. Smith (doi: https://doi.org/10.1176/appi.ajp.2018.18080991) published in the December 2018 issue, the beginning of the second sentence of the last paragraph should have read “However, as the authors point out, currently there is not a single medication with a Food and Drug Administration indication for treating borderline personality disorder[.]” The corrected letter was reposted on December 17, 2018.